Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 24.33
(0.58%)
CNY 24.33
(0.58%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -679.87 Million CNY | 37.42% |
| 2022 | -1.08 Billion CNY | 21.65% |
| 2021 | -1.38 Billion CNY | -528.98% |
| 2020 | -220.45 Million CNY | -279.54% |
| 2019 | -58.08 Million CNY | -11.43% |
| 2018 | -52.12 Million CNY | 37.4% |
| 2017 | -83.26 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 381.34 Million CNY | 234.72% |
| 2024 Q1 | -267.43 Million CNY | 60.66% |
| 2024 Q2 | 161.46 Million CNY | 160.38% |
| 2023 Q2 | -643.85 Million CNY | -55.2% |
| 2023 FY | -679.87 Million CNY | 37.42% |
| 2023 Q4 | -679.87 Million CNY | -15.49% |
| 2023 Q3 | -588.67 Million CNY | 8.57% |
| 2023 Q1 | -414.85 Million CNY | 61.82% |
| 2022 Q2 | -692.5 Million CNY | 3.97% |
| 2022 Q1 | -721.13 Million CNY | 47.99% |
| 2022 FY | -1.08 Billion CNY | 21.65% |
| 2022 Q4 | -1.08 Billion CNY | -102.71% |
| 2022 Q3 | -535.96 Million CNY | 22.61% |
| 2021 FY | -1.38 Billion CNY | -528.98% |
| 2021 Q2 | -410.61 Million CNY | -140.37% |
| 2021 Q4 | -1.38 Billion CNY | -1269.21% |
| 2021 Q3 | -101.26 Million CNY | 75.34% |
| 2021 Q1 | 1.01 Billion CNY | 561.44% |
| 2020 FY | -220.45 Million CNY | -279.54% |
| 2020 Q4 | -220.45 Million CNY | 0.0% |
| 2020 Q2 | -471.64 Million CNY | 0.0% |
| 2019 FY | -58.08 Million CNY | -11.43% |
| 2018 FY | -52.12 Million CNY | 37.4% |
| 2017 FY | -83.26 Million CNY | 0.0% |